Aortic valve disease is the most common form of heart valve disease in developed countries and a growing healthcare burden with an ageing population. Transthoracic and transoesophageal echocardiography remains central to the diagnosis and surveillance of patients with aortic stenosis, providing gold standard assessments of valve haemodynamics and myocardial performance. However, other multimodality imaging techniques are being explored for the assessment of aortic stenosis, including combined PET/CT and PET/MR. Both approaches provide unique information with respect to disease activity in the valve alongside more conventional anatomic assessments of the valve and myocardium in this condition. This review investigates the emerging use of PET/CT and PET/MR to assess patients with aortic stenosis, examining how the complementary data provided by each modality may be used for research applications and potentially in future clinical practice.
introduCtion Aortic stenosis is the most common valvular heart disease in the developed world. The prevalence of aortic sclerosis in the general population is estimated to be 25% at the age of 65 increasing to almost 50% at age 80. The rate of progression to hemodynamically significant aortic stenosis is estimated to be almost 2% per year, translating to a relatively low prevalence (<1%) at age 60 and younger, 1,2 but rising rapidly to >10% for elderly patients aged >75. 3 Aortic stenosis was once thought simply related to ageassociated wear and tear but is now known to be an active, highly regulated process with pathophysiological similarities to atherosclerosis and bone formation. Initial endothelial injury leads to lipid and inflammatory cell infiltration followed by the development of progressive valvular fibrosis and calcification. A progressive vicious cycle of calcification and endothelial injury then ensues leading to progressive valve stiffening and stenosis 4 and consequent left ventricular hypertrophy. Without appropriately timed valve replacement patients end up with symptoms, heart failure and finally death.
In aortic stenosis, imaging of the valve is crucial in ascertaining a diagnosis, grading severity and informing the timing of valvular intervention. 5 In addition, the importance of the myocardial remodelling response to these forms of valve disease is increasingly appreciated. 6 While echocardiography remains the gold standard method for assessing patients with aortic stenosis, CT and MR are being used increasingly to provide complimentary information on valve stenosis severity and myocardial health, respectively. Most recently PET has emerged, providing unique information regarding disease activity in combination with either CT or MR assessments.
In this review, we will focus on how modern advances in PET/CT and PET/MR might improve our pathophysiological understanding of aortic stenosis, aid in the development of novel treatment strategies and ultimately improve the care of patients with aortic stenosis.
How does PET work?
Modern hybrid PET/CT and PET/MR scanners now provide detailed molecular information about the activity of specific disease processes developing in vivo. In principle any biologically active process can be studied depending on the availability of a targeted PET radiotracer. These radiotracers are injected into the body and accumulate in areas of active disease, emitting radiation that can be detected by the PET scanner to create a PET image. This image lack spatial resolution but this is overcome by fusion with
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Tzolos et al an anatomical image provided by either CT or MR, captured with the patient lying in the same position on a single gantry ( Figure 1 ). These scans also offer attenuation correction allowing quantification of tracer concentration in different tissues. Additional CT and MRIsequences now allow combination of the disease activity information from PET with advanced structural information from CT or MR, harnessing all the advantages of these advanced imaging techniques. 7
Developing role of CT and MR in calcific AS
Transthoracic echocardiography (TTE) is generally sufficient enough to assess the aortic valve morphology (tricuspid vs bicuspid) and the haemodynamic assessment of the valve. However, in around a quarter of patients with moderate of severe aortic stenosis, echocardiographic assessments of disease severity are discordant resulting in diagnostic uncertainty. Recently, multidetector CT (MDCT) calcium scoring of the valve (CT-AVC) has emerged as an alternative assessment of aortic stenosis severity to complement echocardiography. CT-AVC provides a quantitative and accurate measurement of aortic valve calcium (AVC) burden, with high intraobserver, interobserver and scan-rescan reproducibility. 8, 9 Sex-specific thresholds for severe disease demonstrate excellent agreement with concordant echocardiography (AUC 0.92 in female and 0.89 in male Pawade et al) 10 and importantly provide strong prediction of disease progression and the need for AVR compared to echocardiography. [11] [12] [13] [14] [15] [16] [17] On this basis, CT-AVC was included in the most recent European Society of Cardiology guidelines for the assessment of patients with discordant echocardiographic measurements. 17 Contrast-enhanced CT angiography is now used as standard in the work up of patients being considered for transcutaneous aortic valve implantation, providing accurate valve sizing, distance to the coronary arteries and assessment of the optimal access route (ref).
Cardiac MR (CMR) can also be used in cases where echocardiographic results are inconclusive. It has multiple advantages, including the ability to measure heart volumes, blood flow and ventricular wall thickness. [18] [19] [20] [21] CMR is a useful tool in the diagnosis and evaluation of bicuspid aortic valve and is invaluable in the assessment of concomitant thoracic aortic dilatation/ aneurysm and mitral valve abnormalities. 22, 23 However, the real strength of CMR lies in the assessment of the myocardium and in particular of myocardial fibrosis. [24] [25] [26] Multiple studies have now shown that midwall fibrosis (as detected through late gadolinium enhancement) serves as an objective marker of left ventricular decompensation and is an independent predictor of mortality in patients with aortic stenosis. 25, [27] [28] [29] The EVOLVED study (Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients with Severe Aortic Stenosis, NCT03094143) aims to assess the clinical outcome of asymptomatic patients with severe aortic stenosis and mid-wall myocardial fibrosis that have either early surgical intervention or routine care.
positron emission tomography
Hybrid imaging platforms such as PET/CT and PET/MR can now incorporate the benefits of both anatomical (CT and MR) and molecular (PET) techniques to provide a comprehensive imaging assessment of aortic stenosis. In particular, the PET component provides assessments of disease activity to complement the anatomic information provided by the other modalities.
Recently, PET has utilised two tracers: 18 F-fluorodeoxyglucose ( 18 F-FDG) to measure inflammation in the valves of patients with aortic stenosis and 18 F-fluoride for calcification activity. 18 F-FDG PET is widely used to image vascular inflammation. This PET tracer is an inactive glucose analogue which concentrates in metabolically active cells and is a well-established, sensitive but non-specific marker of vascular inflammation. Macrophages have higher glucose requirements than surrounding cells in the vasculature, which translates in excellent correlation (r = 0.85, p < 0.001) between the 18 F-FDG signal and macrophage burden on histology (CD68 staining) in carotid atheroma. 30 18F-fluoride has been used both clinical and in oncological research for over 50 years as a bone tracer. Fluoride ions exchange with hydroxyl ions in areas of exposed hydroxyapatite crystal, with binding highest in areas of developing microcalcification due to surface area effects. 31 In preferentially targeting developing microcalcification, 18F-Fluoride PET therefore provides different information to the macrocalcification identified by CT.
PET/CT 18F-FDG PET/CT imaging in aortic stenosis was first explored by Marincheva-Sancheva in 2011. 32 In a retrospective observational study, 84 patients (42 with aortic stenosis and 42 agematched control patients without aortic stenosis) were recruited from a list of subjects who endured PET/CT imaging between 2005 and 2010, primarily for assessment of cancer. Severity of aortic stenosis was established on echocardiography and patients were respectively divided in three groups (mild, moderate and severe aortic stenosis). Overall the AV PET signal, mean Target to Background Ratio (TBR mean ), was higher in patients with aortic stenosis compared to controls: median 1.53 (IQR: 1.42 to 1.76) vs 1.34 (IQR: 1.20 to 1.55); p < 0.001. Interestingly on further assessment, 18F-FDG uptake was higher in patients with mild and moderate aortic stenosis than controls but was no different in those with severe AS. Comparable tendencies were detected when subjects were classified according to AV calcification. Furthermore, compared with the 18F-FDG uptake in non-calcified AVs, TBR was increased in mildly and moderately, but not severely calcified valves. As predicted, there was a significant association between valvular calcification grade and aortic stenosis severity (r = 0.90, p < 0.001). Moreover, in a subset of patients, it was observed that the valvular TBR is increased in patients who afterwards experience progression of aortic stenosis. Patients with high AV TBR had a higher probability of haemodynamic progression of aortic stenosis on repeat echo, performed 1 to 2 years after the baseline echo. Notably, progression of aortic stenosis was noted in five of six patients (83%) with high initial AV TBR and only in two of nine patients (22%) with low TBR (p = 0.04).
This was the first study to demonstrate that 18F-FDG uptake is increased in aortic stenosis, supporting the hypothesis that it is an active inflammatory condition.
Our group has also confirmed the excellent reproducibility and feasibility of PET/CT in the assessment of aortic stenosis, with 18F-FDG and particularly 18F-NaF exhibiting significant potential as novel biomarkers of aortic stenosis progression. 33 In a prospective study, 101 successive patients aged >50 years with different stage of aortic valve disease, ranging from aortic sclerosis to severe aortic stenosis, and 20 age-matched control subjects, had 18F-NaF and 18F-FDG scans less than 1 month apart. 18F-NaF uptake strongly correlated with the stage of the aortic valve disease, with patients with aortic stenosis demonstrating the highest uptake followed by the aortic sclerosis and control subjects (TBR MAX : vs 2.87 ± 0 vs 1.92 ± 0.3182 vs 1.55 ± 0.17, respectively; p < 0.001). In the severe aortic stenosis group (n = 23), 100% of subjects had increased uptake compared to 88% in the mild and moderate groups (n = 55) and 45% in the aortic sclerosis cohort (n = 20).
Although 18F-FDG also showed increased uptake in the valve, a more scattered pattern of activity was observed. We observed similar trends of activity with aortic stenosis demonstrating substantially higher uptake compared with both aortic sclerosis and control subjects. (TBR MAX : 1.58 ± 0.21 vs 1.47 ± 0.15 vs 1.30 ± 0.13, respectively; p < 0.001. Compared to 18F-NaF, the correlation of the uptake with the stage of the aortic stenosis severity was weaker, with only 52% (vs 100% with 18F-NaF) at the severe aortic stenosis group demonstrating increased uptake. Similarly, just below one-third (31%) in the mild and moderate aortic stenosis showed increased uptake and just one-fourth (20%) in the sclerosis group. Interestingly, while 18F-NaF uptake was higher than 18F-FDG uptake in the valve, the reverse was true in areas of atheroma, highlighting importance pathological differences in these two conditions that might justify the disappointing results of statin therapy in aortic stenosis and indicating that therapies targeting calcification directly might prove of greater clinical value. 34 A subsequent follow-up study of this cohort demonstrated that both 18 F-fluoride and 18 F-FDG predicted disease progression and adverse clinical outcomes in aortic stenosis. 35 Disease progression was assessed at 1 and 2 years using AVC scoring and TTE. On repeat CT imaging, new valvular calcium was visible in a similar distribution as the 18 F-fluoride activity on baseline PET imaging. Indeed, baseline 18 F-fluoride uptake correlated strongly with the subsequent rate of progression in AVC (Spearman r = 0.80; p < 0.001) and with echocardiographic measures of haemodynamic progression (mean gradient r = 0.32; p = 0.001). 18F-F-DG-PET showed similar but weaker correlations. (r = 0.43; p < 0.001 and r = 0.26; p = 0.01, respectively). The study also looked at clinical outcomes. The primary clinical outcome endpoint was a composite of cardiovascular death and aortic valve replacement. Average follow-up was 1232 days with 23 patients (17%) having undergone AVR and nine cardiovascular death. 7 Both 18 F-Fluoride and 18 F-FDG were independent predictors of allcause mortality and AVR [HR 1.46 (1.24-1.71); p < 0.001 and HR 1.59 (1.21-2.09); p = 0.002, respectively].
More recent studies have used 18F-NaF to gain insights into the pathophysiology underlying aortic stenosis. Knag et al 36 showed that PET/CT has a promising role in research studies exploring the pathophysiology of aortic stenosis and finding potential medical therapy targets. They showed that in patients with aortic stenosis, lipoprotein(a)[Lp(a)] and oxidised phospholipids (OxPL), drive valve calcification and disease progression. On baseline PET/CT, patients in the top Lp(a) tertile had increased valve calcification activity and increased 18F-NAF uptake, compared with those in lower tertiles. These findings
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Tzolos et al suggest lowering Lp(a) or inactivating OxPL may slow aortic stenosis progression and provide a rationale for clinical trials to test this hypothesis. 36 In addition, 18F-NaF PET/CT has been extended to investigate bioprosthetic valve calcification and degeneration. Indeed 18F-NaF appears to provide a highly sensitive marker of early bioprosthetic valve degeneration correlating well with tissue degeneration on histology and providing a powerful prediction tool of subsequent valvular dysfunction and failure of incremental value to standard approaches. 37 In summary, PET/CT imaging provides unique information with respect to disease activity in aortic stenosis. It provides powerful prediction of disease progression in both native and prosthetic valve, excellent scan-rescan reproducibility for tracer quantification (refs) as well as important biological insights. On this basis, it is being used as a marker of disease activity and efficacy endpoint in several ongoing trials of novel therapies in aortic stenosis. In SALTIRE 2 (NCT02132026) 75 subjects will be randomised (2:1) to either subcutaneous denosumab 60 mg (n = 50) or matched placebo (n = 25) every 6 months; and a further 75 will be randomised (2:1) to oral alendronate 70 mg (n = 50) or matched placebo (n = 25) once week. 18F-NaF uptake will be measured at baseline, and 6 months to assess the early impact of the intervention on valvular calcification activity. Its future role in clinical practice is less clear, given that the simpler technique of CT calcium scoring also provides similar prediction of disease progression and clinical events. However, if advances in the PET/ CT technique including motion correction and co-registration result in improvements such that PET outperforms in CT, then this approach may yet develop a clinical role, with initial results suggesting that this may occur sooner in bioprosthetic rather than native valves.
PET/MR
PET/MR is an emerging technique, combining the excellent temporal and spatial resolution of MRI with the sensitive molecular imaging of PET. In principle, PET/MR offers several potential advantages over PET/CT, in particular superior tissue characterisation, improved motion correction and major reductions in radiation exposure. Furthermore, MR is also more naturally suited to the imaging of certain tissues in the body compared to CT including the left ventricular myocardium. However, the availability of PET/MR is currently limited, and scanners remain expensive. Moreover, several technical challenges remain with cardiac PET/MR scanning as outlined below.
First, the method of PET attenuation correction is different between PET/CT and PET/MR. Unlike CT, MR attenuation correction maps are based on proton density, 38 with two current approaches. The Dixon MR AC map is the standard approach but is hampered in cardiac studies due to both motion artefact (along the heart-lung and liver-lung interfaces) and mis-segmentation of the bronchi as soft tissue. A novel free-breathing radial Gradient Recalled Echo approach has been demonstrated in patients with coronary disease to largely overcome these issues 39 but concerns regarding signal dropout in those with metallic implants such as aortic valve replacements and stents remain.
Second, both cardiac and respiratory motion causes loss of PET signal which subsequently reduces reader confidence in image interpretability. In principle, PET/MR might allow the tracking of motion throughout PET acquisition and therefore its correction. In practice, this has yet to be consistently applied. Finally, PET/MR is a costly technique which requires considerable expertise within centres for both performing and interpreting scans, rendering both research output and clinical adoption slow when compared to PET/CT.
PET/MR of the aortic valve
Despite these limitation PET/MR has demonstrated some early promise in the assessment of patients with aortic stenosis. Doris et al were the first to report increased 18F-fluoride activity on PET/MR in aortic stenosis ( Figure 2 ) and also illustrated the versatility of the technique providing assessments of LV volumes, mass, ejection fraction and LGE burden alongside the valve assessments. Moreover, they demonstrated improved signal-tonoise ratios (SNR) and TBRs over the valve using motion correction approaches derived from the PET. 40 Further studies are now required.
Outside the aortic valve, both 18F-FDG and 18F-fluoride PET/ MR have been shown to delineate areas of infarcted myocardium. 41, 42 In inflammatory disease, 18F-FDG PET/MR has demonstrated major promise in the clinical diagnosis of active cardiac sarcoid combining the advantages of PET and MR LGE. 43, 44 This approach has also shown promise in identifying areas of florid inflammation in myocarditis and endocarditis. 45, 46 Furthermore, 18F-fluoride PET/MR may help differentiate between different subtypes of cardiac amyloid. 47 Given the increasing prevalence (and similar phenotypes) of both aortic stenosis and cardiac amyloid in an ageing population, our group is currently utilising PET/MR to investigate whether 18F-fluoride can distinguish clinically significant aortic stenosis from cardiac amyloid as well as comparing uptake in healthy controls (NCT03352089).
PET/MR holds particular promise in the temporal assessment of chronic slowly progressing conditions such as bicuspid aortic valve disease which is present in 1.4% of live births and contributes significantly to the proportion of patients undergoing aortic valve surgery. [48] [49] [50] The greatly reduced radiation exposure is particularly important given the relatively younger age of the patient at presentation and indeed this is why 18 F-Fluoride PET/ MR is being explored as an efficacy endpoint in the BASIK two trial (Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using 18 F -Sodium Fluoride Positron Emission Tomography/Magnetic Resonance, NCT02917525). 51 Furthermore, the reduced radiation dose afforded through PET/MR may allow the exploration of multiple tracers used simultaneously to enhance our understanding of the temporal relationship between inflammation, fibrosis and calcification within the disease process. However, before PET/MR can be widely applied to cardiovascular disease, it is important to establish whether PET/MR provides similar results to PET/CT. We have therefore recently completed a simultaneous PET/CT and PET/MR validation study in patients with coronary artery disease and aortic stenosis which will report soon (NCT02988531). Moreover, the BASIK2 trial (NCT02917525) is now being conducted to investigate the effect of vitamin K2 supplementation on valvular calcification in patients with bicuspid aortic valve disease. 51 The primary endpoint is the change in PET/MR 18F-NaF uptake (6 months minus baseline).
ConClusion
PET/CT can be used to measure inflammation and valvular calcification activity in patients with aortic stenosis, providing important insights into the pathogenesis of aortic stenosis and a useful surrogate endpoint of disease activity in trials of novel therapies. Moreover 18 F-Fluoride PET provides powerful prediction of disease progression and adverse events, with further development required to demonstrate incremental value to CT calcium scoring. Despite its inferior spatial resolution, PET/MR can provide detailed assessment of both valvular function and hypertrophic response with a lower associated radiation exposure. While in the early stages of its development, PET/MR may emerge as the favoured technique for temporal disease tracking and myocardial assessments. Further research is now warranted using both these exciting techniques to imaging patients with aortic stenosis. 
